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Background: There are safety concerns regarding the use of anticholinergics in the COPD
patient population. The purpose of this review was to evaluate the cardiovascular risk of
regular use of inhaled tiotropium bromide in patients with COPD of any severity.
Methods: Systematic searches were conducted in MEDLINE, EMBASE, the Cochrane Controlled
Trials Register, manufactures’ trial register, and FDA databases, without language restriction.
Primary outcomes were a composite of major adverse cardiovascular events, cardiovascular
mortality, and nonfatal myocardial infarction (MI) or stroke during the treatment period. Rela-
tive risks (RR) were estimated using fixed-effects models and statistical heterogeneity was
estimated with the I2 statistic.l; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; ICS, inhaled corticosteroids;
yocardial infarction; RCTs, randomized controlled trials; RR, relative risk; SF, salmeterol/fluticasone.
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1422 G.J. Rodrigo et al.Results: Nineteen randomized controlled trials (18,111 participants) were selected. There was
no difference in the incidence of adverse cardiovascular events (RRZ 0.96; 95% CI, 0.82e1.12,
I2Z 6%). Among individual components of the composite outcome, tiotropium did not signifi-
cantly increase the risk of cardiovascular death (RRZ 0.93; 95% CI, 0.73e1.20, I2Z 1%),
nonfatal MI (RRZ 0.84; 95% CI, 0.64e1.09, I2Z 0%), and nonfatal stroke (RRZ 1.04; 95% CI,
0.78e1.39, I2Z 0%). A smoking history of 55 pack-years presented a trend to a higher rate
of cardiovascular adverse events in patients receiving tiotropium.
Conclusions: Compared with control (placebo or salmeterol), tiotropium did not significantly
increase the risk of adverse major cardiovascular events among COPD patients. Subgroup anal-
ysis suggested that smoking history can modify the risk of cardiovascular adverse events.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
public health problem.1,2 Current treatments may reduce
symptoms, increase exercise capacity, reduce the number
or severity of exacerbations, and improve the health status
of patients. Treatment guidelines indicate that bronchodi-
lators are the standard of care in COPD patients.1,2
Specifically, anticholinergic agents are of particular value
since vagal cholinergic tone appears to be a reversible
component of airway narrowing.3 Tiotropium bromide,
the most widely prescribed agent for the treatment of
COPD in the world [Boehringer Ingelheim. Annual report
2007. http://www.boehringer-ingelheim.com/corporate/
download/ar/AR2007.pdf [accessed 05.01.09] has been
available in Europe since 2002 and it was approved for use
in the United States in early 2004. It is a synthetic quater-
nary anticholinergic agent with two important character-
istics: it acts through prolonged M3 muscarinic receptor
antagonism,4 and has a long duration of action, making it
appropriate for once daily therapy.5,6 Substantial evidence
from controlled studies in patients with COPD has shown
greater benefits with tiotropium than with placebo, ipra-
tropium or salmeterol.7,8
Although a previous pooled analysis of 19 short-term
placebo-controlled trials revealed no significant increase
in the risk of cardiovascular (CV) adverse events with
tiotropium bromide,9 two recent publications, a nested
caseecontrol study,10 and a systematic review with meta-
analysis11 reported an increased risk for all-cause and CV
mortality, myocardial infarction (MI) and stroke in COPD
patients who received tiotropium or inhaled anticholiner-
gics. Nevertheless, these studies have received critics like
inability to adjust for the duration of the treatment or
double-counting of trials. On the contrary, a recent pool
analysis12 which combines data from the tiotropium trials
included in the Singh meta-analysis11 with published data
from the UPLIFT (Understanding Potential Long-term
Impacts on Function with Tiotropium) trial13 concludes that
tiotropium does not carry CV risks. However, this analysis
did not include information on its methodology, and only
assessed composite outcomes. Thus, accounting for these
contradictory and limited messages regarding the security
of inhaled anticholinergics, we performed an independent
systematic review (according to the QUOROM statements14)
to evaluate the safety of regular use of inhaled tiotropium
bromide in patients with any severity of COPD.Methods
Search strategy and eligibility criteria
The search was conducted using different strategies. First,
we searched MEDLINE (1966eMay 2009), EMBASE (1980e
May 2009) and Cochrane Controlled Trials Register
(CENTRAL) (second quarter 2009) databases using the
following MeSH, full text and keyword terms: tiotropium
bromide OR Spiriva AND COPD OR chronic obstructive
pulmonary disease. Second, a search of relevant files from
Boehringer Ingelheim (http://trials.boehringer-ingelheim.
com/com/Home/TrialResults/index.jsp) and FDA (www.
fda.gov) clinical trials databases was performed. Third,
reviews and texts were searched for citations. Finally, we
contacted the manufacturer of tiotropium and obtained
data from an updated integrated tiotropium clinical trial
database. Trials published solely in abstract form were
excluded because methods and results could not be fully
analyzed. The search was without language restriction and
unpublished studies were included.
The specific inclusion criteria were: 1) adult patients
aged greater than 35 years with stable COPD satisfying
American Thoracic Society/European Respiratory Society,
or GOLD diagnostic criteria1,2; 2) intervention: inhaled
tiotropium bromide as the intervention drug compared with
placebo or long-acting beta agonists (LABA) or LABA plus
inhaled corticosteroid (ICS); 3) length of treatment: studies
with more than 4 weeks of duration; 4) design: randomized
(parallel group or cross-over) controlled trials (RCT); 5)
primary outcomes: major adverse CV outcome composite
(composite of nonfatal MI, stroke and CV death), CV
mortality (including sudden death), nonfatal MI, and
nonfatal stroke (including transient ischemic attack) during
treatment period. All-cause mortality was determined as
a secondary outcome.Data extraction and validity assessment
Titles, abstracts, and citations were independently
analyzed by all reviewers. From full text, they indepen-
dently assessed studies for inclusion based on the criteria
for population, intervention, study design and outcomes.
Any disagreement over study inclusion was resolved by
consensus. Two reviewers (GJR and LJN) extracted data
from the selected studies and assessed each study for the
Figure 1 Flowchart for identification of usable studies.
Safety of tiotropium in COPD 1423sequence generation, allocation sequence concealment,
blinding, incomplete outcome data, and selective outcome
reporting and other potential sources of bias.15 In the case
of multiple published or unpublished reports for a partic-
ular study, data from the most recent version were
extracted.
Data analysis
All outcomes were pooled using common relative risk (RR)
and 95% confidence interval (CI). If pooled effect estimates
for dichotomous outcomes were significantly different
between groups, we calculated the number needed to harm
(NNH) to cause an event. Heterogeneity was tested by
means of the DerSimonian and Laird Q statistic. Heteroge-
neity was further measured by using the I2 test.16 Values of
50% or more indicate a substantial level of heterogeneity.
Without substantial heterogeneity, data were combined by
mean of a fixed-effects model17; otherwise, a random-
effects model was used.18 A predefine sensitivity analysis
was conducted to explore the influence of the following
factors: the effect size for concealment allocation15
(adequate vs. unclear), trial duration (long-term >6 months
to 4 years vs. short-term 6 weeks to 6 months), concomitant
use of inhaled corticosteroids (55% of patients vs. <55% of
patients) and smoking history (55 pack-years vs. <55
pack-years). Subgroups were compared using the interac-
tion test.19 A p value< 0.05 using a two-tailed test was
considered to indicate significance. This meta-analysis was
performed with the Review Manager 5.0.20 (Nordic
Cochrane Centre, Copenhagen, Denmark).
Results
A total of 19 RCT including 18,111 patients met the
inclusion criteria and were selected for analysis (Fig. 1).
Of them, fifteen studies compared tiotropium vs.
placebo,13,23e36 two studies compared tiotropium vs.
salmeterol/fluticasone (SF),20,37 one study compared tio-
tropium vs. salmeterol vs. placebo,22 and one compared
tiotropium vs. salmeterol.21 Two trials were unpublished.32,33
There was a total agreement between the reviewers on
inclusion of studies. Some of the selected studies reported
results for patients enrolled in previous trials. Thus, Casaburi
et al.23 reported combined results from Casaburi et al.38 and
a similar unpublished trial. Likewise, Brusasco et al.22
presented combined results of Donohue et al.39 and a similar
unpublished trial. Therefore, only Casaburi et al.23 and
Brusasco et al.22 studies were included in the analysis.
There were seven long-term trials13,23,25,28,31,32,34
(28 weeks to 48 months) and twelve short-term
trials20e22,24,26,27,29,30,33,35e37 (8 weeks to 6 months) (Table 1).
The mean age of patients was 64.8 years (74% of males),
with an average baseline FEV1 of 41% of predicted normal
values. Regarding allocation concealment, it was adequate
in only 4 studies13,30,34,37 and unclear in the remaining
fifteen. Withdrawal rate was available for all trials and
ranged from 0% to 45.1%. The withdrawal rate was lower with
tiotropium than with placebo (25.4% vs. 31.1%, pZ 0.0001)
or salmeterol (12.4% vs. 16.0%, pZ 0.05). Contrary, the
withdrawal rate was significantly higher with tiotropiumcompared with SF (38.6% vs. 33.0%, pZ 0.03). Tiotropium
was administered once a day via a HandiHaler device
(Boehringer Ingelheim, Ingelheim am Rhein, Germany,
18 mcg) in 18 studies, and via the Respimat device (Boeh-
ringer Ingelheim, Ingelheim am Rhein, Germany, 5 or 10 mcg)
in one study.36
Primary outcomes
Data from fifteen studies13,20,22e26,28e32,34,36,37 with 15,695
patients (thirteen comparing tiotropium vs. placebo)
showed no significant difference in the incidence of major
composite adverse CV events between the tiotropium and
control groups (3.6% vs. 4.0% respectively) (Fig. 2). The
post-hoc subgroup analysis (based in thirteen trials that
compared tiotropium with placebo) (Table 2) did not show
significant differences regarding the duration of treatment,
allocation concealment, and concomitant use of ICS. On the
contrary, studies with COPD patients with a smoking his-
tory 55 pack-years presented a trend to a higher rate of
composite CV events. It is to emphasize that the analysis of
the two studies20,37 that compared tiotropium with SF
showed an opposite effect with a significant higher inci-
dence of adverse events in the tiotropium group.
Among individual components of the composite
outcome, ten studies13,22,23,29e32,34,36,37 involving 13,356
patients (nine studies comparing tiotropium vs. placebo)
showed that inhaled tiotropium did not significantly
increase the risk of CV death (1.7% vs. 1.9% respectively)
Table 1 Characteristics of selected studies.a
First author
[Reference]
Location and
duration
Patients, n
(% male)
Mean
age, y
Mean baseline
FEV1,%
predicted
Smoking history Withdrawal
rate (%)
Allocation
concealment
Bateman20 12 centers; 6 wk T: 56 (67.9) 62.4 45.9 57.1% 0 Unclear
SF:51(74.5) 62.5 48.8 45.1 3.9
Briggs21 50 centers; 12 wk T: 328 (65.0) 64.2 37.7 55.6 pack-yrs 8.8 Unclear
S: 325 (68.0) 64.6 37.7 56.1 pack-yrs 12.6
Brusasco22 18 countries; 24 wk T: 402 (77.4) 63.8 39.2 44.1 pack-yrs 15.4 Unclear
S: 405 (75.1) 64.1 37.7 44.8 pack-yrs 18.8
Pl: 400 (76.3) 64.6 38.7 42.4 pack-yrs 25.7
Casaburi23 50 centers; 52 wk T: 550 (66.5) 65.0 39.1 63.0 pack-yrs 18.7 Unclear
Pl: 371 (62.8) 65.0 38.1 59.0 pack-yrs 27.8
Casaburi24 17 centers; 25 wk T: 55 (54.5) 65.9 32.6 58.7 pack-yrs 14.5 Unclear
Pl: 53 (58.5) 67.3 36.2 58.8 pack-yrs 16.9
Chan25 101 centers; 48 wk T: 608 (59.0) 66.8 39.4 50.2 pack-yrs 27.5 Unclear
Pl: 305 (61.0) 66.9 39.4 51.0 pack-yrs 22.2
Covelli26 12 centers; 12 wk T: 100 (66.0) 65.8 40.2 66.0 pack-yrs 10.0 Unclear
Pl: 96 (49.0) 63.3 38.6 65.0 pack-yrs 17.7
Criner27 20 centers; 8 wk T: 80 (75.0) 61.8 41.9 45.6 pack-yrs 5.0 Unclear
Pl: 86 (60.5) 63.2 41.1 47.1 pack-yrs 8.1
Dusser28 177 centers; 54 wk T: 500 (89.0) 64.5 48.2 27% 23.4 Unclear
Pl: 510 (87.0) 65.0 47.6 24% 28.8
Moita29 31 centers; 12 wk T: 144 (95.0) 63.6 41.4 57.1 pack-yrs 7.5 Unclear
Pl: 160 (94.0) 64.8 41.3 54.8 pack-yrs 6.7
Niewoehner30 26 centers; 26 wk T: 915 (99.0) 68.1 35.6 69.4 pack-yrs 26.7 Adequate
Pl: 914 (98.0) 67.6 35.6 67.4 pack-yrs 16.6
Powrie31 Single centre; 52 wk T: 69 (69.6) 66.3 50.9 54.6 pack-yrs 30.4 Unclear
Pl: 73 (56.2) 66.4 49.2 55.7 pack-yrs 28.7
Spiriva 205e25032 2 centers; 28 wk T: 76 (82.8) 64.6 39.6 33.0 pack-yrs 15.7 Unclear
Pl: 76 (82.8) 64.6 39.6 33.0 pack-yrs 15.7
Spiriva 205e25733 294 centers; 12 wk T: 1236 (76.0) 62.2 46.4 NS 18.1 Unclear
Pl: 403 (74.0) 62.3 44.4 NS 22.3
Tashkin13 490 centers; 48 mo T: 2986 (75.4) 64.5 39.5 49.0 pack-yrs 36.8 Adequate
Pl: 3006 (73.9) 64.5 39.3 48.4 pack-yrs 45.1
Tonnel34 123 centers; 40 wk T: 266 (86.8) 64.9 47.5 44.4 pack-yrs 14.6 Adequate
Pl: 288 (85.4) 63.5 46.2 43.0 pack-yrs 25.6
Vogelmeier35 86 centers; 24 wk T: 221 (79.2) 63.4 51.6 38.6 pack-yrs 13.1 Unclear
Pl: 209 (77.5) 62.5 51,.1 40.1 pack-yrs 12.9
Voshaar36 64 centers; 12 wk T: 360 (70.5) 64.0 39.5 52.5 pack-yrs 9.4 Unclear
Pl: 181 (69.0) 63.0 42.0 51 pack-yrs 12.1
Wedzicha37 20 countries; 24 mo T: 665 (84) 65.0 39.4 39.5 pack-yrs 41.9 Adequate
SF: 658 (81) 64.4 39.1 41.3 pack-yrs 35.2
a PlZ placebo; moZmonths; NSZNot stated; SZ salmeterol; SFZ salmeterol/fluticasone; TZ tiotropium; wkZweeks; yrsZ years.
1424 G.J. Rodrigo et al.(Fig. 3). On the other hand, inhaled tiotropium did not
significantly increase the risk of nonfatal MI compared with
placebo, or salmeterol or SF (1.6% vs. 2.0% respectively)
(Fig. 4). Finally, the incidence of nonfatal stroke was
equivalent with tiotropium than with controls (1.8% vs. 1.8%
respectively) (Fig. 5). There was no evidence of statistical
heterogeneity among the included trials for any of these
end points. Because one study13 contributed with the
largest weight in the fixed-effects model, we excluded it in
a new analysis limited to the remained trials. However, this
exclusion did not change the primary conclusions on
adverse CV composite (RRZ 1.31; 95% CI, 0.94e1.81,
I2Z 0%, pZ 0.57), CV mortality (RRZ 1.68; 95% CI,0.98e2.78; I2Z 0%, pZ 0.08), MI (RRZ 0.94; 95% CI,
0.59e1.52; I2Z 0%, pZ 0.81), and stroke (RRZ 1.12; 95%
CI, 0.43e2.90; I2Z 0%, pZ 0.81) respectively.
Secondary outcome
Tiotropium did not significantly increase the risk of all-
cause mortality (RRZ 0.97; 95% CI, 0.86e1.09; I2Z 20%,
pZ 0.61) in meta-analysis of sixteen studies13,21e25,27,29e37
involving 17,051 patients. Once more, a study comparing
tiotropium with SF37 showed a significant higher incidence
of all-cause deaths in the tiotropium group (RRZ 1.87; 95%
CI, 1.07e3.28, pZ 0.03). Finally, the exclusion of the study
Figure 2 Pooled relative risk for major adverse composite cardiovascular events (with 95% confidence interval) of eligible studies
comparing inhaled tiotropium with control.
Safety of tiotropium in COPD 1425by Tashkin et al.13 did not modify the conclusion
(RRZ 1.15; 95% CI, 0.85e1.57; I2Z 18%, pZ 0.33).Discussion
This is the largest systematic review with meta-analysis
designed to evaluate the safety of regular use of tiotropium
bromide in patients with COPD of any severity. Our analysis
included 19 RCT (comparing tiotropium with placebo, or
with salmeterol or with SF), with more than 18,000
patients, and found that tiotropium did not increase the
risk of CV mortality, nonfatal CV events (MI and stroke), and
all-cause mortality compared with controls. However,
because most of included studies compared tiotropium with
placebo, these conclusions are based mainly in this
comparison. However, when we included in the analysis
data from four studies20e22,37 that compare tiotropium with
salmeterol or SF, the summary effect estimate did not
change, without evidence of clinical and statistical
heterogeneity between trials. A more detailed analysis
showed that contrary to the tiotropium vs. salmeterol
comparisons that presented similar conclusions to tio-
tropium vs. placebo comparisons, tiotropium vs. SFcomparisons20,37 displayed an opposite tendency. Thus, the
use of SF was associated with a non-significant lower inci-
dence in CV mortality37 and MI incidence.20e37 In a similar
way, the Wedzicha et al. trial37 showed a significant
decrease in the all-cause mortality rate compared with
tiotropium, suggesting a protective effect of ICS. Although
the withdrawal rate was similar between tiotropium and SF
in a 6-week trial,20 in the 2-year Wedzicha study37 the
withdrawal rate was significantly higher with tiotropium
compared with SF (due to COPD exacerbations, perceived
lack of efficacy, or unwillingness to remain in the study).
Conversely, there was a small but significant increase in
reported pneumonia in the SF-treated group.
The influence on the results was explored through
sensitivity analysis (Table 2). Although limited by its post-
hoc nature, the subgroup analysis suggests that some
factors could modify the risk of CV adverse events. Thus,
while there were no significant differences between short
and long-term trials, adequate or unclear allocation
concealment, and concomitant use of ICS, data suggested
that the risk could be modified according the CV risk profile
of patients. Thus, patients with a smoking history of 55
pack-years presented a trend to a higher incidence of major
CV adverse events.
Figure 3 Pooled relative risk for cardiovascular mortality (with 95% confidence interval) of eligible studies comparing inhaled
tiotropium with control.
1426 G.J. Rodrigo et al.The results of our review contradict a recent meta-
analysis that focused on the CV safety of anticholinergics in
COPD. Specifically, Singh et al.11 performed a systematic
review on the basis of 17 selected RCT, and concluded that
anticholinergics (tiotropium and ipratropium) are associ-
ated with a significantly increased risk of CV death, MI or
stroke. However, there were several important differences
between the Singh et al. study and our current analysis. 1)
Singh et al.11 performed a pool analysis of a mix of studies
that compared tiotropium vs. placebo (eight studies), tio-
tropium vs. salmeterol (one study), tiotropium vs. SF (one
study), tiotropium vs. salmeterol vs. placebo (two studies),
ipratropium vs. placebo (one study), ipratropium vs. sal-
meterol (one study), and ipratropium vs. albuterol vs.
placebo (three studies). So, placebo-controlled trials were
pooled together with active controlled trials, assuming that
the comparator drug is interchangeable with a placebo. 2)
On the contrary, we focus our analysis exclusively to tio-
tropium comparisons (vs. placebo, salmeterol or SF). 3) The
meta-analysis by Singh et al. showed a significant increase
in the nonfatal or fatal cardiovascular risk based in the
ipratropium vs. control comparison (RRZ 1.70; 95% CI,
1.19e2.42, I2Z 0%, pZ 0.003). Contrary, in the same
analysis, twelve studies that compared tiotropium vs.
control (placebo or salmeterol or SF) did not show a signif-
icant higher incidence of adverse severe cardiovascular
events (RRZ 1.43; 95% CI, 0.95e2.16; pZ 0.08; I2Z 0%,
pZ 0.08). The difference in the CV events was primaryderived from four (three comparing tiotropium with pla-
cebo23,25e31 and one with SF37) long-term studies (duration
of study> 6 months). Furthermore, the difference in CV
events could be due to bias. Thus, Oba et al.12 found
evidence of possible publication bias when long-term
studies were analyzed statistically and graphically. 4) Two
of the twelve included studies38,39 presented redundant
data and should have been excluded. 5) Our review added 9
new RCT studies13,21,24,27,28,32e35 with more than 10,000
patients. 6) The Singh et al. study11 assessed as a primary
outcome measure a composite of nonfatal major adverse
CV events and CV death; additionally, the risk of all-cause
mortality was determined as a secondary outcome. Our
review not only includes these two outcomes but also adds
to the analysis the incidence of MI, stroke and CV deaths. 7)
In the Singh et al. review, the number of the control group
in the study by Chan et al.25 was 305 instead 350.
Our review meets most of the methodological criteria
suggested for scientific reviews.14 We selected seven new
published and two unpublished RCT that reported at least
one fatal or nonfatal CV event, with more than 10,000 new
COPD patients; additionally, we excluded two redundant
studies33,34 selected in a previous review.11 All of the
selected studies were RCT and combined with no evidence
of clinical and statistical heterogeneity between trials,
increasing the confidence of our findings. Among the
studies added, the UPLIFT trial13 is the longest (4-year) and
largest study (almost 6000 patients with COPD) that
Figure 4 Pooled relative risk for nonfatal myocardial infarction (with 95% confidence interval) of eligible studies comparing
inhaled tiotropium with control.
Figure 5 Pooled relative risk for stroke (with 95% confidence interval) of eligible studies comparing inhaled tiotropium with
control.
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Table 2 Sensitivity analysis. Comparisons between Relative Risks (RR) in composite adverse cardiovascular events stratified by
concealment allocation (adequate vs. unclear), trial duration (long-term >6 months to 4 years vs. short-term 6 weeks to 6
months), concomitant use of inhaled corticosteroids (55% vs. <55% of patients), and smoking history (55 pack-years vs. <55
pack-years).
Subgroup comparisons RR (95%CI) Interactive
test17 RR (95%CI)
p
Adequate13,30,34 vs.
unclear22e26,28,29,31,32,36
0.87 (0.74e1.04), I2Z 0% vs. 1.15 (0.73e1.82), I2Z 4% 1.32 (0.81e2.15) 0.26
Long-term13,23,25,28,31,32,34 vs.
short-term22,24,26,27,29,30,33e36
0.90 (0.76e1.07), I2Z 24% vs. 1.10 (0.54e2.28), I2Z 0% 1.22 (0.58e2.56) 0.59
55%13,26,28,30,31 vs. <55% of
patients22e25,28,32,34,36
0.89 (0.75e1.06), I2Z 0% vs. 2.91 (0.88e9.57), I2Z 0% 1.20 (0.72e2.00) 0.47
<55 pack-years13,22,25,28,31,32,34,36 vs.
55 pack-years23,24,26,29,30
0.87 (0.74e1.03), I2Z 0% vs. 1.51 (0.79e2.81), I2Z 0% vs. 1.73 (0.90e3.37) 0.09
1428 G.J. Rodrigo et al.compared inhaled tiotropium with placebo. However, the
UPLIFT study is different from previous tiotropium trials.
Thus, because its protocol allowed the use of short acting
anticholinergics for the treatment of COPD exacerbations,
the potential cardiotoxic effect of these drugs adminis-
tered in both arms, could potentially mask the CV adverse
effects of tiotropium. However, after we excluded this
study, the conclusions did not change through the different
outcomes assessed.
There are some potential limitations that come from the
fact that none of these trials were specifically designed to
monitor CV events, therefore, the reporting of CV outcomes
may have been incomplete. Also, the fact that most of
included studies reported adverse effects only during the
treatment period could increase the probability of bias.
Finally, the fact that 80% of the reviewed patients were
men limits the applicability of results since COPD is sus-
pected to affect men and women equally.
In summary, the conclusions of this review were: 1)
inhaled tiotropium did not increase the risk of major
adverse CV events (MI, stroke, CV deaths) and all-cause
mortality. 2) Unlike other comparisons (tiotropium vs.
placebo or salmeterol), the use of SF was associated with
a lower incidence in CV events and all-cause mortality
compared with tiotropium, suggesting a protective effect
of ICS. Conversely, there was a small but significant
increase in reported pneumonia in the SF-treated group.
Nevertheless, these conclusions are based mainly in data
from one study. 3) Subgroup analysis suggests that the
smoking history could modify the risk of CV adverse events.
So, caution should be advised in patients at risk for CV
disease. The same is true for SF in patients at high risk for
pneumonia. 4) Because none of the trials were prospec-
tively designed to assess the CV risk of inhaled anticholin-
ergics in patients with COPD, CV outcomes may not have
been prospectively defined in a uniform fashion across the
trials. Adequately designed randomized trials prespecified
on CV outcomes will allow to clarify completely this issue.Conflict of interests
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